In 2024, Hikma Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Hikma Pharmaceuticals has also provided a category-level breakdown for 9 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021-2019 |
|---|---|---|---|---|
Total Scope 1 | 38,468a | 43,830a | 42,346a | |
Total Scope 2 | ||||
Market-Based | 81,804a | 79,897a | 78,140a | |
Location-Based | 87,237a | 83,536a | 79,601a | |
Total Scope 3 | 860,710a | 836,978a | 783,917a | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 12.3019a | 15.2452a | 22.823a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2024, the total operational greenhouse gas (GHG) emissions of Hikma Pharmaceuticals amounted to 125,705 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Hikma Pharmaceuticals decreased by 1.3%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a
In 2024, the total Scope 1 emissions of Hikma Pharmaceuticals were 38,468 metric tons of CO₂ equivalent (tCO₂e).a
Since 2020, Hikma Pharmaceuticals's Scope 1 emissions have decreased by 18.8%, reflecting a declining long-term trend in Scope 1 emissions over time.a
Compared to the previous year (2023), Hikma Pharmaceuticals's Scope 1 emissions decreased by 12.23%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a
In 2024, Hikma Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 81,804 tCO₂e using the market-based method and 87,237 tCO₂e using the location-based method.a
Since 2020, Hikma Pharmaceuticals's Scope 2 greenhouse gas (GHG) emissions (Location-Based) have remained relatively stable, indicating that Hikma Pharmaceuticals's emissions have plateaued with no significant change in its energy consumption footprint.a
Compared to the previous year (2023), Hikma Pharmaceuticals's Scope 2 emissions (Location-Based) have remained relatively stable, indicating that Hikma Pharmaceuticals's emissions have plateaued with no significant change in its energy consumption footprint.a
In 2024, Hikma Pharmaceuticals reported its Scope 2 emissions using the market-based method and using the location-based method.a
In 2024, Hikma Pharmaceuticals reported 860,710 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2024 disclosure of Hikma Pharmaceuticals includes a breakdown across 9 of the 15 Scope 3 categories defined by the GHG Protocol, up from 7 in 2023, reflecting improved emissions accounting practices and greater transparency across the company's value chaina
In 2024, Hikma Pharmaceuticals reported total Scope 3 emissions of 860,710 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 94.15% of these emissions originated from upstream activities such as purchased goods and capital goods, while 5.85% came from downstream activities like product use, distribution, and end-of-life treatment.a
Compared to the previous year (2023), Hikma Pharmaceuticals's Scope 3 emissions remained relatively stable, indicating that Hikma Pharmaceuticals's emissions have plateaued with no significant change in its value chain footprint.a
In 2024, Hikma Pharmaceuticals reported emissions for 9 out of the 15 Scope 3 categories defined by the GHG Protocol.a
This partial disclosure allows for some insight into the company's indirect impacts.
In 2024, the largest contributors to Hikma Pharmaceuticals's Scope 3 emissions were:a
In 2024, Hikma Pharmaceuticals reported Scope 1 greenhouse gas (GHG) emissions of 38,468 tCO₂e and total revenues of USD 3,127 millions. This translates into an emissions intensity of 12.3 tCO₂e per millions USD.a
In 2024, Hikma Pharmaceuticals reported a Scope 1 emissions intensity of 12.3 tCO₂e per millions USD. Compared to the peer group median of 14.22, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
In 2024, Hikma Pharmaceuticals ranked 10 out of 22 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
Hikma Pharmaceuticals is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a
In 2024, Hikma Pharmaceuticals reported a total carbon footprint of 986,415 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 2.29% increase compared to 2023, suggesting a rise in emissions across its operations or value chain.a
The largest contributor to Hikma Pharmaceuticals's total carbon footprint was Scope 3 emissions, accounting for 87.26% of the company's total carbon footprint, followed by Scope 2 emissions at 8.84%.a